Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2021

View Archived Issues

Antidiarrheal drug fights AML

New phase I study evaluates iExosomes in metastatic pancreatic cancer with KrasG12D mutation

Oral islatravir studied in new phase III trials as PrEP for HIV

New CRL4 inhibitors show cytotoxicity tumors with low CUL4 expression

Copper chelator TDMQ-20 reverses impairments in Alzheimer's disease models

Positive phase I data support advancing FOR-6219 to phase II development in endometriosis

Dosing begins in phase I study of DNX-2440 in patients with resectable liver metastasis

Landos reports positive phase I data for NX-13

Bi-functionalized nanoparticles described by Vall d'Hebron Institut de Recerca and collaborators

Eli Lilly presents promising data from SURPASS-2 study of tirzepatide in type 2 diabetes

University of Virginia patents regulatory T cells armed with bispecific antibodies

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology describe mu-opioid agonists

New JAK-1/TYK2 inhibitors synthesized at the National Institute of Pharmaceutical R&D

Cough triggers and symptoms among patients treated in COUGH-1 and COUGH-2

New NTRK1 inhibitors discovered by Luoxin Pharmaceutical, Shandong Luoxin Pharmacy Group

CYH-33 demonstrates preliminary antitumor activity in PIK3CA-mutant tumors

[68Ga]NOTA-AE-105 PET/MRI useful for prostate cancer evaluation and reduces biopsy needs

Youhe reports partial remission in phase I study of YH-001 with teriprizumab in solid tumors

Apellis ends development of APL-9 for severe COVID-19

FDA approves Actemra for systemic sclerosis-associated interstitial lung disease

NIAID closes ACTIV-3 substudies of BRII-196, BRII-198 and VIR-7831

Novel mutation in the IRF2BPL gene tied to rare neurodevelopmental disorder

Imperial psychedelic microdosing study pushes the envelope on participant blinding

TurnSole initiates phase I/II study of TS-020 in hospitalized COVID-19 patients

NervGen receives FDA feedback on phase I plans with NVG-291

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...